ClariVest Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

ClariVest Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-26,908	Closed	-$2.43M	–	796
2021 Q3	$2.43M	Sell	26,908 -6,003	-18%	-$543K	0.08%	217
2021 Q2	$3.14M	Sell	32,911 -181	-0.5%	-$18.9K	0.1%	177
2021 Q1	$3.77M	Buy	33,092 +2,727	+9%	+$371K	0.13%	146
2020 Q4	$4.2M	Sell	30,365 -8,823	-23%	-$1.05M	0.14%	124
2020 Q3	$3.22M	Buy	+39,188	New	+$3.25M	0.11%	153
2016 Q3	–	Sell	-12,552	Closed	-$613K	–	739
2016 Q2	$613K	Buy	12,552 +1,700	+16%	+$110K	0.02%	350
2016 Q1	$687K	Buy	10,852 +6,391	+143%	+$418K	0.02%	328
2015 Q4	$501K	Sell	4,461 -106	-2%	-$10.6K	0.01%	347
2015 Q3	$440K	Buy	+4,567	New	+$523K	0.01%	338

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ClariVest Asset Management's RARE Position: Q4 2021 in Review

ClariVest Asset Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 26,908 shares — an estimated $2.43M sold.

ClariVest Asset Management first reported a position in RARE in Q3 2015 and held it in 9 quarters. The position peaked at $4.2M in Q4 2020. 234 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

ClariVest Asset Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
ClariVest Asset Management sold 26,908 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $2.43M.
ClariVest Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 9 quarters.
ClariVest Asset Management's Ultragenyx Pharmaceutical position peaked at $4.2M in Q4 2020.
234 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on ClariVest Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.